KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to $495.7 million.

  • AbCellera Biologics' Cash & Equivalents fell 2292.93% to $495.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $495.7 million, marking a year-over-year decrease of 2292.93%. This contributed to the annual value of $625.6 million for FY2024, which is 1774.57% down from last year.
  • According to the latest figures from Q3 2025, AbCellera Biologics' Cash & Equivalents is $495.7 million, which was down 2292.93% from $553.1 million recorded in Q2 2025.
  • In the past 5 years, AbCellera Biologics' Cash & Equivalents registered a high of $1.0 billion during Q2 2022, and its lowest value of $495.7 million during Q3 2025.
  • Its 5-year average for Cash & Equivalents is $721.7 million, with a median of $723.0 million in 2021.
  • In the last 5 years, AbCellera Biologics' Cash & Equivalents surged by 6770.64% in 2022 and then tumbled by 2292.93% in 2025.
  • AbCellera Biologics' Cash & Equivalents (Quarter) stood at $723.0 million in 2021, then increased by 22.62% to $886.5 million in 2022, then fell by 14.2% to $760.6 million in 2023, then decreased by 17.75% to $625.6 million in 2024, then dropped by 20.77% to $495.7 million in 2025.
  • Its Cash & Equivalents was $495.7 million in Q3 2025, compared to $553.1 million in Q2 2025 and $605.3 million in Q1 2025.